IL274550B2 - Dopamine-b-hydroxylase inhibitors - Google Patents

Dopamine-b-hydroxylase inhibitors

Info

Publication number
IL274550B2
IL274550B2 IL274550A IL27455020A IL274550B2 IL 274550 B2 IL274550 B2 IL 274550B2 IL 274550 A IL274550 A IL 274550A IL 27455020 A IL27455020 A IL 27455020A IL 274550 B2 IL274550 B2 IL 274550B2
Authority
IL
Israel
Prior art keywords
methyl
hydrogen
optionally substituted
alkyl
compound
Prior art date
Application number
IL274550A
Other languages
English (en)
Hebrew (he)
Other versions
IL274550A (en
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720189.8A external-priority patent/GB201720189D0/en
Priority claimed from GBGB1804439.6A external-priority patent/GB201804439D0/en
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of IL274550A publication Critical patent/IL274550A/en
Publication of IL274550B2 publication Critical patent/IL274550B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL274550A 2017-12-04 2020-05-10 Dopamine-b-hydroxylase inhibitors IL274550B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720189.8A GB201720189D0 (en) 2017-12-04 2017-12-04 Dopamine-B-hydroxylase inhibitors
GBGB1804439.6A GB201804439D0 (en) 2018-03-20 2018-03-20 Dopamin-b-hydroxylase inhibitors
PCT/PT2018/050043 WO2019112457A1 (en) 2017-12-04 2018-11-30 Dopamine-β-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
IL274550A IL274550A (en) 2020-06-30
IL274550B2 true IL274550B2 (en) 2023-06-01

Family

ID=65012066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274550A IL274550B2 (en) 2017-12-04 2020-05-10 Dopamine-b-hydroxylase inhibitors

Country Status (16)

Country Link
US (2) US11434242B2 (cg-RX-API-DMAC10.html)
EP (1) EP3720856A1 (cg-RX-API-DMAC10.html)
JP (1) JP7167155B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200096584A (cg-RX-API-DMAC10.html)
CN (1) CN111479812A (cg-RX-API-DMAC10.html)
AU (1) AU2018379646A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020010216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3082337A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020001461A1 (cg-RX-API-DMAC10.html)
IL (1) IL274550B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020005864A (cg-RX-API-DMAC10.html)
PH (1) PH12020500542A1 (cg-RX-API-DMAC10.html)
RU (1) RU2020121820A (cg-RX-API-DMAC10.html)
SG (1) SG11202004231YA (cg-RX-API-DMAC10.html)
TW (1) TW201925193A (cg-RX-API-DMAC10.html)
WO (1) WO2019112457A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
TW202528310A (zh) * 2023-09-20 2025-07-16 美商深蘋果治療股份有限公司 經取代胺化合物,組合物及使用方法
WO2025161144A1 (zh) * 2024-01-29 2025-08-07 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2449689A1 (fr) 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4628059A (en) 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
ES2201104T3 (es) 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
WO2008085008A1 (en) * 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
NZ583193A (en) 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors

Also Published As

Publication number Publication date
SG11202004231YA (en) 2020-06-29
WO2019112457A1 (en) 2019-06-13
CA3082337A1 (en) 2019-06-13
BR112020010216A2 (pt) 2020-09-15
US20230138795A1 (en) 2023-05-04
US11434242B2 (en) 2022-09-06
US20210171528A1 (en) 2021-06-10
TW201925193A (zh) 2019-07-01
JP7167155B2 (ja) 2022-11-08
PH12020500542A1 (en) 2021-01-25
CL2020001461A1 (es) 2020-10-16
EP3720856A1 (en) 2020-10-14
MX2020005864A (es) 2020-09-09
IL274550A (en) 2020-06-30
KR20200096584A (ko) 2020-08-12
AU2018379646A1 (en) 2020-06-11
RU2020121820A (ru) 2022-01-10
JP2021505568A (ja) 2021-02-18
CN111479812A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
HRP20192336T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
US11547704B2 (en) Chemical compounds
ES2901197T3 (es) Moduladores alostéricos de los receptores nicotínicos de la acetilcolina
AU2007334402B2 (en) Methods of using MEK inhibitors
CA2902103C (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HRP20170363T1 (hr) Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret)
ES2887578T3 (es) Compuestos de amida para el tratamiento de infecciones por VIH
AU2017279027A1 (en) Chemical Compounds
DK2812337T3 (en) Furo [3,2-B] pyridine derivatives as TBK1 AND IKK INHIBITORS
CA2831966C (en) Thiazole derivatives
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
CA2903979A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2018225093A1 (en) Chemical compounds as atf4 pathway inhibitors
MX2008013400A (es) Derivado de azolcarboxamida.
JP2014505037A5 (cg-RX-API-DMAC10.html)
JP2016523911A5 (cg-RX-API-DMAC10.html)
ES2714705T3 (es) Inhibidor de PDE4 novedoso
RU2019114600A (ru) Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора
WO2019008507A1 (en) 2- (4-CHLOROPHENOXY) -N - ((1- (2- (4-CHLOROPHENOXY) ETHYNAZETIDIN-3-YL) METHYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF ATF4 FOR THE TREATMENT OF CANCER AND D OTHER DISEASES
CA2647036A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
CA3131059A1 (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
JP2021505568A5 (cg-RX-API-DMAC10.html)
IL274198B2 (en) Use of Nox inhibitors to treat cancer
RU2020121820A (ru) Ингибиторы дофамин-в-гидроксилазы
CA2856357A1 (en) 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives